03.21.18

Children’s Hospital Los Angeles Treats First Patient on the West Coast Using Gene Therapy

Source: Children’s Hospital Los Angeles

Surgeons of The Vision Center at Children's Hospital Los Angeles completed a revolutionary gene replacement procedure on Tuesday, March 20 at 9:20 am, to restore vision in a patient with retinal degeneration, using the first gene therapy ever approved for a genetic condition in the United States.

The breakthrough one-time treatment replaces a defective gene called RPE65 located in the retina, the membrane at the back of the eye that detects light and color, with a healthy copy made from artificial DNA, the equivalent of human DNA. RPE65 is responsible for producing a protein that makes light receptors work in the eye.

"We are pleased to be able to offer this therapy that can truly impact a patient’s quality of life and, potentially, help them see their future through ‘new eyes’," Thomas C. Lee, MD, director of The Vision Center at CHLA and associate professor of ophthalmology at the USC Roski Eye Institute, said in a news release.

Of the seven hospitals nationwide approved to deliver this therapy to patients, CHLA is the only one with two full-time, dedicated pediatric retinal surgeons on site — Aaron Nagiel, MD, PhD and Dr. Lee. CHLA also is home to the Center for Personalized Medicine, where a laboratory certified by the Clinical Laboratory Improvement Amendments (CLIA) can do the necessary genetic testing for potential patients to determine if they have the defective RPE65 gene.

Although Dr. Nagiel and Dr. Lee specialize in treating children and adolescents, the first patient to undergo the gene replacement procedure at CHLA on March 20 was an adult. The patient was unable to access the revolutionary therapy at a facility closer to his home, so CHLA's Vision Center offered their expertise in order to bridge this gap.

"This inherited condition begins to manifest during childhood and adolescence,” said Dr. Nagiel, who also heads a predictive medicine research program at CHLA that is working toward the next breakthroughs in restoring functional sight. “But since there has been no available treatment, there is a tremendous backlog of people who have been waiting many years, and we want to help respond to that urgent need."

The patient, who has Leber congenital amaurosis (LCA), can see large objects in the right lighting conditions. But his vision continues to deteriorate, and this procedure represents the last opportunity to stabilize his sight and prevent total blindness.

This therapy helped restore vision in a clinical trial for people between the ages of 4 and 44 with LCA caused by RPE65 mutations. Following treatment, participants reported recognizing faces, seeing stars and being able to read for the first time in years.

The therapy is administered through a surgical procedure and patients are discharged later that same day with an eye patch protecting the treated eye. Approximately one week later, the patient returns to have the procedure performed on their second eye.

The vision-restoring RPE65 gene therapy, marketed as Luxturna, was developed by Spark Therapeutics. The procedure gained marketing approval from the FDA in 2017 for both children and adults with a defective RPE65 gene.

Related Content